정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 842 | Terminated | Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection | SARS-CoV-2 | Other: Standard of care Drug: Hydroxychloroquine Drug: Azithromycin |
Phase 2 | Duke University | OTHER | 11 | All | 12 Years | Duke Regional Hospital, Durham, North Carolina, United States Duke University Hospital, Durham, North Carolina, United States Durham VA Medical Center, Durham, North Carolina, United States Duke Raleigh Hospital, Raleigh, North Carolina, United States |
| 841 | Not yet recruiting | Prasugrel in Severe COVID-19 Pneumonia | Thrombosis | Drug: Prasugrel Hydrochloride 10 MG Oral Tablet Drug: Placebo |
Phase 3 | Azienda Ospedaliera Universitaria Integrata Verona, University of Milan | OTHER | 128 | All | 18 Years ~ 99 Years | Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy |
| 840 | Recruiting | Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) | COVID-19 | Drug: Prazosin Other: Standard of care |
Phase 2 | Johns Hopkins University, Fast Grants | OTHER | 220 | All | 45 Years ~ 85 Years | Johns Hopkins Hospital, Baltimore, Maryland, United States |
| 839 | Recruiting | Predictive Immune Biomarkers for COVID-19 Pathogenesis | COVID-19 | Biological: Blood collection on admission and longitudinally Biological: Blood collection on their first consultation and 10 to 14 days later |
Not Applicable | University Hospital, Toulouse | OTHER | 400 | All | 18 Years | Purpan University Hospital, Toulouse, France |
| 838 | Completed | Prednisolone in Early Diffuse Systemic Sclerosis | Systemic Sclerosis | Drug: Prednisolone 5 mg Drug: Placebo oral capsule; From August 2020 'no additional treatment' |
Phase 2 | Prof. Ariane herrick, Versus Arthritis | OTHER | 35 | All | 18 Years | Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, Aberdeenshire, United Kingdom Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom Glasgow Royal Infirmary -, Glasgow, Lanarkshire, United Kingdom Aintree University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom Royal National Hospital For Rheumatic Diseases - Royal United Hospitals Bath NHS Foundation Trust, Bath, Somerset, United Kingdom Royal Hallamshire Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom Freeman Hospital - The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, United Kingdom Southmead Hospital Bristol - North Bristol NHS Trust, Bristol, United Kingdom Ninewells Hospital and Medical School - NHS Tayside, Dundee, United Kingdom Royal Free London NHS Foundation Trust, London, United Kingdom |
| 837 | Terminated | Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada) | Coronavirus | Drug: Hydroxychloroquine Drug: Placebo oral tablet |
Phase 3 | McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Manitoba, University of Alberta, University of British Columbia, McMaster University, Lawson Health Research Institute, Eastern Health, University of Minnesota | OTHER | 70 | All | 18 Years | University of Minnesota, Minneapolis, Minnesota, United States University of Alberta, Edmonton, Alberta, Canada University of British Columbia, Vancouver, British Columbia, Canada University of Manitoba, Winnipeg, Manitoba, Canada Eastern Health, Saint John's, Newfoundland and Labrador, Canada McMaster University, Hamilton, Ontario, Canada Lawson Health Research Institute, London, Ontario, Canada Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada |
| 836 | Recruiting | PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS | SARS-CoV-2 Infection (COVID-19) | Drug: Colchicine plus symptomatic treatment (paracetamol) Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) |
Phase 3 | Instituto de Investigacion Marques de Valdecilla, Gerencia de atencion primaria area 1, Gerencia de atencion primaria area 2, Gerencia Atencion Primaria Area 3, Gerencia de atencion primaria area 4 | OTHER | 954 | All | 60 Years | Atencion primaria (Area 2), Laredo, Cantabria, Spain Gerencia de atencion primaria (Area 3), Reinosa, Cantabria, Spain Atencion primaria (AREA 1), Santander, Cantabria, Spain Gerencia de atencion primaria (area 4), Torrelavega, Cantabria, Spain |
